TOPLINE:

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated consistent efficacy and safety regardless of diuretic type or dose and reduced overall diuretic requirements in patients with heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), although it had no effect on the initiation of a new loop diuretic.

METHODOLOGY:

Investigators conducted a secondary analysis of the multinational FINEARTS-HF trial to evaluate the efficacy and tolerability of finerenone in patients with HFmrEF/HFpEF who were on diuretics.

The analysis included 5438 patients (mean age, 72.1 years; 45.9% women) who had HF classified as New York Heart Association class II through IV, used diuretics within 30 days of randomization, had a left ventricular ejec

See Full Page